Pipeline

Disease area

Product

Compound

Indication

Phase I

Phase II

Phase III

Filing 

Migraine

 

Eptinezumab

Eptinezumab is an investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide (CGRP). 

 

 

      

      

Agitation in dementia of the Alzheimer’s type

 

 

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Find the specific study here: www.clinicaltrials.gov/NCT03548584 and www.clinicaltrials.gov/NCT03594123

            

Post-Traumatic Stress Disorder

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of Post-Traumatic Stress Disorder.

 

      

     

 
Borderline Personality Disorder Rexulti Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of Borderline Personality Disorder. 

Read the specific study here www.clinicaltrials.gov/NCT04100096

 

            

Parkinson's Disease

 

Foliglurax

Foliglurax is a small-molecule positive allosteric modulator of group III metabotropic glutamate receptor 4 (mGluR4 PAM) for the potential oral treatment of Parkinson's disease.

Read the specific study here: www.clinicaltrials.gov/NCT03162874

 

      

 

 
Schizophrenia  

Lu AF11167

Lu AF11167 is a potent and selective inhibitor of the PDE10 enzyme and is in development as a monotherapy treatment of negative symptoms in clinically stable (positive symptom controlled) patients with schizophrenia.

Read the specific study here www.clinicaltrials.gov/NCT03793712

 

      

   
Tourette Syndrome   Lu AG06466

The lead molecule Lu AG06466 is a potent selective inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL) that potentiates endocannabinoid signalling to restore homeostatic balance in the central nervous system. 

Read the specific study here https://clinicaltrials.gov/NCT03625453

          
Alzheimer's Disease   Lu AF87908

Lu AF87908 (TAU mAb) is an antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

            
Cognitive Impairment Associated Schizophrenia   Lu AF88434

Lu AF88434 is an inhibitor of the phosphodiesterase type 1 (PDE1) enzyme which is naturally present in the human brain where it plays an important role in the communication between brain cells. Inhibiting the enzyme increases the presence of a chemical messenger within the cells that improves the communication, in turn improving the cognitive function.

            
Migraine   Lu AG09222

LU AG09222 (PACAP) is an early-stage monoclonal antibody (mAb) designed to inhibit pituitary adenylate cyclase-activating polypeptide for migraine prevention. PACAP has emerged as an important signaling molecule in the pathophysiology of migraine and represents an attractive novel target for treating migraine.

            

Schizophrenia 2 months

Abilify Maintena

Aripiprazole once-monthly

Aripiprazole once-monthly is an intramuscular injection indicated for the treatment of schizophrenia once-monthly. It is further in development as a potential 2 months’ treatment of schizophrenia.

      

 

 

 

Parkinson’s Disease

  Lu AF28996

Lu AF28996 is a D1/D2 agonist in development targeting moderate to advanced Parkinson’s disease patients with motor fluctuations.

Read the specific study here: www.clinicaltrials.gov/NCT03565094

      

     

Parkinson’s Disease

  Lu AF82422

Lu AF82422 is a human IgG1 mAb that recognizes all major species of alpha-synuclein. Extracellular alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease.

Read the specific study here www.clinicaltrials.gov/NCT03611569

      

 

   
Neuropathic Pain   Lu AG06466 The lead molecule Lu AG06466 is a potent selective inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL) that potentiates endocannabinoid signalling to restore homeostatic balance in the central nervous system.             

 

 

 

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.